Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Identifieur interne : 001D74 ( Ncbi/Checkpoint ); précédent : 001D73; suivant : 001D75Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
Auteurs : Gregor Simonis [Allemagne] ; Joerg T. Fuhrmann ; Ruth H. StrasserSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Cross-Sectional Studies, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Drug Combinations, Echocardiography, Ergolines (adverse effects), Ergolines (therapeutic use), Ergot Alkaloids (adverse effects), Ergot Alkaloids (therapeutic use), Heart Valve Diseases (chemically induced), Heart Valve Diseases (epidemiology), Humans, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Pergolide (adverse effects), Pergolide (therapeutic use), Product Surveillance, Postmarketing.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Ergolines, Ergot Alkaloids, Pergolide.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Ergolines, Ergot Alkaloids, Pergolide.
- chemically induced : Heart Valve Diseases.
- drug therapy : Parkinson Disease.
- epidemiology : Heart Valve Diseases, Parkinson Disease.
- Cross-Sectional Studies, Drug Combinations, Echocardiography, Humans, Product Surveillance, Postmarketing.
Abstract
Valvular heart disease in patients being treated with ergot-derivative dopamine agonists (Ergot-DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross-sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross-sectional studies including 477 patients treated with Ergot-DA, 127 patients with non-Ergot-DA, and 364 control patients were analyzed. Moderate-to-severe valvular changes were detected in 26% of patients treated with Ergot-DA, 10% of patients treated with non-Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross-sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot-DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed.
DOI: 10.1002/mds.21639
PubMed: 17659636
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002585
- to stream PubMed, to step Curation: 002585
- to stream PubMed, to step Checkpoint: 002720
- to stream Ncbi, to step Merge: 001D74
- to stream Ncbi, to step Curation: 001D74
Links to Exploration step
pubmed:17659636Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.</title><author><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany. gsimonis@gmx.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden</wicri:regionArea><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Dresde</region><settlement type="city">Dresde</settlement></placeName></affiliation></author><author><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T" last="Fuhrmann">Joerg T. Fuhrmann</name></author><author><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H" last="Strasser">Ruth H. Strasser</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21639</idno><idno type="RBID">pubmed:17659636</idno><idno type="pmid">17659636</idno><idno type="wicri:Area/PubMed/Corpus">002585</idno><idno type="wicri:Area/PubMed/Curation">002585</idno><idno type="wicri:Area/PubMed/Checkpoint">002720</idno><idno type="wicri:Area/Ncbi/Merge">001D74</idno><idno type="wicri:Area/Ncbi/Curation">001D74</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.</title><author><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden, Germany. gsimonis@gmx.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medicine/Cardiology, Heart Center, University of Technology, Dresden</wicri:regionArea><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Dresde</region><settlement type="city">Dresde</settlement></placeName></affiliation></author><author><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T" last="Fuhrmann">Joerg T. Fuhrmann</name></author><author><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H" last="Strasser">Ruth H. Strasser</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cross-Sectional Studies</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Combinations</term><term>Echocardiography</term><term>Ergolines (adverse effects)</term><term>Ergolines (therapeutic use)</term><term>Ergot Alkaloids (adverse effects)</term><term>Ergot Alkaloids (therapeutic use)</term><term>Heart Valve Diseases (chemically induced)</term><term>Heart Valve Diseases (epidemiology)</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Pergolide (adverse effects)</term><term>Pergolide (therapeutic use)</term><term>Product Surveillance, Postmarketing</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Ergolines</term><term>Ergot Alkaloids</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Ergolines</term><term>Ergot Alkaloids</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Heart Valve Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Heart Valve Diseases</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cross-Sectional Studies</term><term>Drug Combinations</term><term>Echocardiography</term><term>Humans</term><term>Product Surveillance, Postmarketing</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Valvular heart disease in patients being treated with ergot-derivative dopamine agonists (Ergot-DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently published studies and to determine its clinical relevance. Medline searches were performed to identify cross-sectional, echocardiographic studies comparing patients treated with dopamine agonists or controls, in terms of valvular changes. Observational studies of valve changes in Parkinsonian patients were used to estimate the incidence of severe valvulopathy. The results from 7 cross-sectional studies including 477 patients treated with Ergot-DA, 127 patients with non-Ergot-DA, and 364 control patients were analyzed. Moderate-to-severe valvular changes were detected in 26% of patients treated with Ergot-DA, 10% of patients treated with non-Ergot DA, and 10% of control patients. Severe valvulopathy was less than 1% both in cross-sectional and observational studies. The high rate of moderate valvular changes in patients treated with Ergot-DA suggests that close surveillance of the patients is required. Severe valvulopathy was less than 1% in the studies analyzed.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Dresde</li><li>Saxe (Land)</li></region><settlement><li>Dresde</li></settlement></list><tree><noCountry><name sortKey="Fuhrmann, Joerg T" sort="Fuhrmann, Joerg T" uniqKey="Fuhrmann J" first="Joerg T" last="Fuhrmann">Joerg T. Fuhrmann</name><name sortKey="Strasser, Ruth H" sort="Strasser, Ruth H" uniqKey="Strasser R" first="Ruth H" last="Strasser">Ruth H. Strasser</name></noCountry><country name="Allemagne"><region name="Saxe (Land)"><name sortKey="Simonis, Gregor" sort="Simonis, Gregor" uniqKey="Simonis G" first="Gregor" last="Simonis">Gregor Simonis</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001D74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:17659636
|texte= Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:17659636" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |